In this Seminar, we highlight the main developments in the field of Alzheimer's disease. The
most recent data indicate that, by 2050, the prevalence of dementia will double in Europe …

Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Extracellular neuritic plaques composed of amyloid‑β (Aβ) protein and intracellular
neurofibrillary tangles containing phosphorylated tau protein are the two hallmark proteins of …

Brain aging is a complex process that affects everything from the subcellular to the organ
level, begins early in life, and accelerates with age. Morphologically, brain aging is primarily …

Aging is the most prominent risk factor for late-onset Alzheimer's disease. Aging associates
with a chronic inflammatory state both in the periphery and in the central nervous system, the …

Neurological and psychiatric diseases have high degrees of genetic and pathophysiological
heterogeneity, irrespective of clinical manifestations. Traditional medical paradigms have …

The pathology of Alzheimer disease (AD) damages structural and functional brain networks,
resulting in cognitive impairment. The results of recent connectomics studies have now …

The global epidemic of Alzheimer disease (AD) is worsening, and no approved treatment
can revert or arrest progression of this disease. AD pathology is characterized by the …

For optimal design of anti-amyloid-β (Aβ) and anti-tau clinical trials, we need to better
understand the pathophysiological cascade of Aβ-and tau-related processes. Therefore, we …

Background. Alzheimer's disease (AD) is a progressive neurodegenerative disorder
affecting many individuals worldwide with no effective treatment to date. AD is characterized …